|
 |
European Pharmaceutical Contractor
|
Being a typical Eastern European country, Bulgaria has been kept apart from mainstream clinical research for a long time. This isolation was based on the perception that either to work under the conditions of Bulgaria's political regimen was undesirable, or its sequential economic and respectively clinical standards were not reliable enough to meet the high GCP requirements.
However, this perception is quite likely to be fading away with time, in light of the democratic changes in Central and Eastern Europe. Bulgaria was 'discovered' by the pharmaceutical companies and contract research organisations (CROs) in 1995. Medical departments of most large and mid-sized companies were established, many CROs increased their activity in Bulgaria, and some of them opened local offices there.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Milen Vrabevski, Medical Director of Comac Medical Ltd., in Sofia, Bulgaria
Dr Milen Vrabevski is Medical Director of Comac Medical Ltd., a full service small CRO based in Sofia, Bulgaria. He has over five years of experience in the pharmaceutical industry, mainly in the field of clinical research.
After graduating from the Medical University of Varna in 1995, Milen began his career working as a Junior Doctor in a surgery department, and then as a Medical Representative of a pharmaceutical company before founding Comac Medical Ltd. in 1997, assuming the position of Director.
Being one of the pioneers in the GCP and Quality of Life (QoL) area in his country, Milen has participated in conducting all company clinical studies and QoL projects.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Aegate Proves Authenticating Drugs at the Point of Dispensing Protects Consumers
More info >> |
|
 |
